SU056

• CAT Number: I041739
• CAS Number: 2376580-08-2
• Molecular Formula: C20H16FNO5
• Molecular Weight: 369.34
• Purity: ≥95%
• Synonyms: 8-(3-fluorophenyl)-2-(2-hydroxyethyl)-5,12,14-trioxa-2-azatetracyclo[7.7.0.03,7.011,15]hexadeca-1(16),3(7),9,11(15)-tetraen-6-one
• InChI: InChI=1S/C20H16FNO5/c21-12-3-1-2-11(6-12)18-13-7-16-17(27-10-26-16)8-14(13)22(4-5-23)15-9-25-20(24)19(15)18/h1-3,6-8,18,23H,4-5,9-10H2
• InChIKey: WVJVLSHRAJOEEW-UHFFFAOYSA-N
• SMILES: C1C2=C(C(C3=CC4=C(C=C3N2CCO)OCO4)C5=CC(=CC=C5)F)C(=O)O1

SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015)[1].
SU056 (0-10 μM approximately, 48 h) inhibits cell growth in OVCAR3/4/5/8, SKOV3 and ID8 cells[1]。
SU056 (1 μM, 5-8 days) inhibits colony formation in a dose-dependent manner in OVCAR-8 and ID8 cells[1]。
SU056 (1-5 μM, 6 h) arrests OVCAR8, SKOV3, and ID8 cells in the sub-G1 and G1 phases[1].
SU056 (0-1 μM, 12 h) inhibits cell migration in OVCAR8, SKOV3, and ID8 cells[1].
SU056 (0-5 μM, 24 h) induces apoptotic cell death in OVCAR8, SKOV3, and ID8 cells[1].
SU056 (1-5 μM, 12 h) inhibited the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells[1].
SU056 (0.1, 0.5, and 1 μM, 48 h) enhances the cytotoxic effects of Paclitaxel (HY-B0015) (0.1, 0.5, and 1 nM)[1].
SU056 (20 mg/kg, i.p.) inhibits tumor growth in mice implanted with ID8 cells[1].
SU056 (10 mg/kg, i.p., daily) combined with Paclitaxel (HY-B0015) (5 mg/kg, weekly, i.p.) shows a much greater reduction in OC tumor growth in immunodeficiency mice implanted with OVCAR8 OC tumors[1].

Reference

[1]. Tailor D, et al. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chem Biol. 2021 Aug 19;28(8):1206-1220.e6.
 [Content Brief]